Monopar Therapeutics (MNPR) Insider Trades, Congress & Funds

Smart money at a glance

Filings to Oct 31, 2026

Net selling: insiders sold $4M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.

Company insidersSEC Form 4, last 90 days: -$4M netNet selling
CongressSTOCK Act, last 180 days: NoneNo trades disclosed
Big fundsSEC 13F, latest quarter: NoneNo large changes
Federal contractsUSAspending.gov, last 12 months: No awardsNone on record

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Questions about MNPR filings

Are insiders buying or selling Monopar Therapeutics Inc (MNPR) stock?

Net selling: insiders sold $4M and bought $0 of MNPR stock on the open market in the 90 days to Oct 31, 2026, according to SEC Form 4 filings. $4M of the sales were made under pre-set Rule 10b5-1 trading plans. The largest was Robinson, Chandler (Chief Executive Officer), who sold $2.6M. The latest filing was on Oct 5, 2026.

Which members of Congress have traded MNPR recently?

None. No member of Congress disclosed a MNPR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this MNPR smart-money data?

This summary uses filings available on Oct 31, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.

Smart money on MNPR

Lean short1 source:
- Insiders

Top traders
No tracked positions at the last update
Insiders
Lean short3 sales · $3.7M
3 of 3 on scheduled plans. Form 4 filings.
Politicians
No recent politician filings found
Funds
No recent fund filings found
Fin-fluencers
No recent posts found

Each bar is 100% of that source’s money. The notch marks an even split.

Lean is the direction of the latest moves. Descriptive, not advice.

Questions about MNPR filings

Are insiders buying or selling Monopar Therapeutics Inc (MNPR) stock?

Which members of Congress have traded MNPR recently?

None. No member of Congress disclosed a MNPR trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.

How current is this MNPR smart-money data?

Insiders

What insiders are doing

5 trades · 6 mo

Sold$4.0M

Sells (3)

SC
Starr Christopher M
Dir · Cluster · Oct 5
$659K
sold
RC
Robinson Chandler
Chief Executive Officer · Cluster · Sep 29
$2.6M
sold
TK
Tsuchimoto Kim R
Dir · Cluster · Aug 27
$456K
sold

2 more trades

Pro opens all of them for $16.50/month, paid yearly.

Unlock all 2 trades

Unlock everything for $29/month

Unlock for $29/month

Reported Aug 11, 2026

Earnings came in 7.5% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K Every filing

Last report

Aug 11, 2026

Period ending

Jun 30, 2026

Earnings per share

-$0.62+7.46% beat

-$0.67 expected

Revenue (6M)

$0.00

6M ended Jun 30, 2026 · SEC filing

Next report

Estimated report: Nov 12, 2026, in 12 days

Previous reports

Quarter / reported	Earnings per share	Beat or miss	Revenue / income	Revenue vs last year
Jun 30, 2026Reported Aug 11, 2026	-$0.62est. -$0.67	+7.46%beat	$0.00 · 6MSEC filing	No year-ago quarter
Mar 31, 2026Reported May 14, 2026	-$0.46est. -$0.90	+48.75%beat	$0.00SEC filing	No year-ago quarter
Dec 31, 2025Reported Mar 27, 2026	-$0.61est. -$0.51	-19.61%miss	$0.00 · FYSEC filing	No year-ago quarter
Sep 30, 2025Reported Nov 13, 2025	-$0.48est. -$0.40	-20.00%miss	Not on file	Not on file
Jun 30, 2025Reported Aug 12, 2025	-$0.35est. -$0.48	+27.08%beat	Not on file	Not on file
Mar 31, 2025Reported May 13, 2025	-$0.38est. -$0.57	+33.33%beat	Not on file	Not on file
Dec 31, 2024Reported Mar 31, 2025	-$2.75est. -$0.42	-$2.33miss	$0.00 · FYSEC filing	No year-ago quarter
Sep 30, 2024Reported Nov 8, 2024	-$1.85est. -$1.17	-58.12%miss	Not on file	Not on file

Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.

Open: $73.90
52-wk high: $124.82
High: $75.32
52-wk low: $50.07
Low: $70.65
Prev close: $73.39
Mkt cap: $482.7M
ROE: -19.5%
Beta: 1.51
P/B: 3.8x
Profit margin: +0.0%
Op margin: +0.0%

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $483M

Valuation

P/B3.76

Quality

Operating margin0.0%
ROE-19.5%
ROA-14.6%

Growth

Beta1.51

Technicals

Price structure

This stock is under pressure.

Trend

Under pressure

0 / 100

RSI 14

36balanced

20D volatility

49%annualized

52-week range

$71.91

$50.07$124.82

20D support

$68.81recent floor

20D resistance

$85.49recent ceiling

Returns

5D -0.9%20D -7.8%60D -39.7%

Price vs moving averages

SMA20 -3.8%SMA50 -21.7%SMA200 -6.9%

Volume pace

0.93xvs prior 20D

Quarter / reported

Earnings per share

Beat or miss

Revenue / income

Revenue vs last year

Jun 30, 2026Aug 11, 2026

-$0.62est. -$0.67

+7.46%

$0.00 · 6MSEC filing

No year-ago quarter

Mar 31, 2026May 14, 2026

-$0.46est. -$0.90

+48.75%

$0.00SEC filing

No year-ago quarter

Dec 31, 2025Mar 27, 2026

-$0.61est. -$0.51

-19.61%

$0.00 · FYSEC filing

No year-ago quarter

Sep 30, 2025Nov 13, 2025

-$0.48est. -$0.40

-20.00%

Not on file

Jun 30, 2025Aug 12, 2025

-$0.35est. -$0.48

+27.08%

Not on file

Mar 31, 2025May 13, 2025

-$0.38est. -$0.57

+33.33%

Not on file

Dec 31, 2024Mar 31, 2025

-$2.75est. -$0.42

-$2.33

$0.00 · FYSEC filing

No year-ago quarter

Sep 30, 2024Nov 8, 2024

-$1.85est. -$1.17

-58.12%

Not on file

Monopar Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about MNPR filings

Smart money on MNPR

Questions about MNPR filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 7.5% above what analysts expected.

Estimated report: Nov 12, 2026, in 12 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Monopar Therapeutics Inc

Smart money at a glance

What do analysts expect?

Questions about MNPR filings

Smart money on MNPR

Questions about MNPR filings

What insiders are doing

How top traders are positioned

Unlock everything for $29/month

Earnings came in 7.5% above what analysts expected.

Estimated report: Nov 12, 2026, in 12 days

Previous reports

Is the business strong?

Price structure

Ask it in Claude or ChatGPT.

Monopar Therapeutics Inc

Overview

Questions about MNPR filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.

Monopar Therapeutics Inc

Overview

Questions about MNPR filings

Smart money

Unlock everything for $29/month

Earnings

Previous reports

Financials

Technicals

Ask it in Claude or ChatGPT.